On 11 March, Seed Capital Bizkaia, in its aim to promote business initiatives with an innovative vocation, invested in 3% of Mikrobiomik’s shares. “It is of the utmost interest to us to support companies like Mikrobiomik. They are a clear example of the promotion of business initiatives with an innovative vocation that we seek with our investment vehicle”, says Oscar Ugarte, CEO of Seed Capital Bizkaia. In the words of Juan Basterra, CEO of Mikrobiomik, “the entry of Seed Capital Bizkaia means that Mikrobiomik will be able to complete phase III of its leading product, MBK-01, with the aim of being the first company in the world to market the first biological medicine based on intestinal microbiota in the EU”. Furthermore, Basterra stresses, “the fact that a Regional Public Company is participating in Mikrobiomik is a vote of confidence in our project and encourages us to pursue our dream of reaching the market in the shortest possible time”.